virus
known
common
caus
respiratori
ill
throughout
world
season
variat
mark
temper
rather
tropic
climat
virus
caus
ill
rang
brief
upper
respiratori
tract
infect
sever
system
ill
result
death
risk
infect
often
relat
age
influenza
exampl
known
highest
attack
rate
amongst
young
old
mcintyr
et
al
respiratori
syncyti
viru
rsv
affect
mainli
young
although
less
typic
infect
amongst
adult
recogn
hall
risk
infect
also
depend
preexist
medic
condit
immunocompet
histor
laboratori
diagnosi
respiratori
infect
slow
relianc
viru
isol
serolog
techniqu
use
immunofluorescencebas
assay
improv
turnaround
time
nasopharyng
aspir
requir
optim
result
method
suffer
limit
number
virus
detect
reagent
avail
avail
new
class
drug
activ
influenza
b
virus
preclin
clinic
trial
drug
target
respiratori
virus
influenza
hayden
et
al
cianci
et
al
uckun
et
al
potenti
new
vaccin
power
et
al
encourag
shorter
diagnost
turnaround
time
detect
respiratori
virus
increas
number
diagnost
laboratori
use
polymeras
chain
reaction
pcr
base
assay
rapidli
identifi
wide
rang
virus
specimen
collect
varieti
respiratori
site
billaud
et
al
echavarria
et
al
vuorinen
et
al
result
retrospect
studi
respiratori
virus
specimen
obtain
individu
live
victoria
australia
present
season
virus
detect
occurr
age
group
present
hospit
patient
compar
particip
influenza
surveil
program
occurr
dual
infect
investig
specimen
receiv
individu
includ
victoriawid
influenza
surveil
program
oper
may
septemb
year
watt
et
al
patient
admit
victorian
hospit
respiratori
ill
acquir
infect
nosocomi
admiss
tabl
clinic
materi
sent
laboratori
test
hospit
patient
includ
nose
swab
throat
swab
nasopharyng
aspir
npa
endotrach
aspir
bronchoalveolar
lavag
bal
bronchial
wash
lung
biopsi
sputum
sampl
pleural
fluid
nose
throat
swab
nt
pool
viral
transport
medium
receiv
surveil
patient
taken
individu
symptom
day
less
fever
cough
fatigu
multipl
sampl
singl
patient
sent
test
one
result
includ
analysi
total
addit
respiratori
specimen
includ
asymptomat
laboratori
staff
use
valid
pcr
assay
influenza
viru
subtyp
influenza
b
viru
rsv
parainfluenza
virus
least
one
type
picornavirus
mixtur
enterovirus
rhinovirus
adenovirus
differ
serotyp
tabl
iii
pcr
assay
develop
valid
clinic
materi
nt
npa
bal
parallel
exist
techniqu
viru
isol
lewi
kennett
andor
immunofluoresc
perform
use
bartel
viral
respiratori
screen
identif
kit
triniti
biotech
counti
wicklow
ireland
process
includ
design
evalu
primer
optim
nucleic
acid
extract
condit
establish
optimum
pcr
amplif
condit
evalu
applic
specimen
type
determin
assay
sensit
compar
convent
assay
specif
test
use
clinic
materi
like
neg
includ
asymptomat
staff
volunt
materi
previous
shown
posit
respiratori
virus
convent
assay
sequenc
amplifi
product
confirmatori
method
avail
lack
immunofluoresc
routin
isol
method
confirm
pcr
posit
human
metapneumoviru
hmpv
human
coronaviru
type
human
coronaviru
type
sequenc
pcramplifi
product
virus
carri
second
round
primer
use
deriv
product
sequenc
obtain
confirm
comparison
nation
center
biotechnolog
inform
genebank
databas
prior
test
specimen
spike
low
copi
number
bovin
diarrheal
diseas
viru
bvdv
act
intern
control
nucleic
acid
extract
revers
transcript
pcr
amplif
step
approach
use
nonhuman
viru
intern
inhibit
control
report
previous
druce
et
al
viral
nucleic
acid
extract
use
one
two
commerci
avail
method
prefer
method
use
magnapur
lc
autom
extract
robot
total
nucleic
acid
isol
kit
roch
diagnost
mannheim
germani
involv
extract
viral
nucleic
acid
ml
clinic
materi
viral
transport
medium
elut
final
volum
ml
suppli
elut
buffer
specimen
contain
inhibitor
pcr
shown
failur
bvdv
intern
control
amplifi
reextract
column
highpur
viral
nucleic
acid
extract
column
roch
diagnost
retest
ten
microlit
rna
linear
min
ad
ml
revers
transcript
master
mix
consist
random
hexam
roch
diagnost
dntp
amersham
bioscienc
buckinhamshir
uk
amvrt
enzym
buffer
promega
madison
wi
incub
min
follow
min
cdna
product
store
test
adenoviru
dna
extract
either
method
surviv
process
result
shown
panel
nest
pcr
assay
capabl
detect
respiratori
virus
develop
use
primer
report
other
design
inhous
tube
includ
influenza
viru
subtyp
zhang
evan
influenza
b
viru
zhang
evan
adenovirus
allard
et
al
bvdv
intern
control
cleland
et
al
tube
includ
rsv
osiowi
picornavirus
primer
specif
enterovirus
rhinovirus
ireland
et
al
tube
includ
parainfluenza
viru
type
tube
includ
tube
includ
hmpv
requir
separ
pcr
assay
use
distinguish
enterovirus
rhinovirus
picornaviru
compon
tube
posit
zoll
et
al
steining
et
al
neg
control
nucleasefre
water
includ
everi
assay
viru
posit
control
consist
low
copi
number
cdna
dna
adenoviru
includ
relev
pcr
target
viru
primer
use
first
second
round
amplif
geneproduct
target
list
tabl
ii
first
round
amplif
ml
cdna
templat
ad
ml
mastermix
contain
nm
first
round
primer
nm
picornaviru
primer
mm
mgcl
mm
dntp
u
taq
polymeras
qiagen
hilden
germani
first
round
pcr
condit
consist
one
cycl
min
follow
cycl
sec
sec
sec
min
condit
tube
reduc
sec
respect
cycl
second
round
amplif
ml
first
round
product
transfer
fresh
mastermix
contain
second
round
primer
second
round
pcr
amplif
condit
round
except
cycl
compon
tube
reduc
cycl
anneal
temperatur
reduc
separ
amplifi
materi
molecular
weight
marker
roch
diagnost
perform
electrophoresi
min
agaros
gel
prestain
ethidium
bromid
gel
photograph
use
gel
doc
biorad
hercul
ca
total
patient
specimen
examin
tabl
year
specimen
receiv
hospit
patient
particip
influenza
surveil
program
conduct
mayseptemb
specimen
receiv
femal
male
particip
surveil
program
convers
specimen
hospit
male
patient
overal
respiratori
viru
detect
rate
higher
specimen
receiv
surveil
patient
hospit
patient
year
respect
surveil
patient
compar
respect
hospit
patient
experi
carri
develop
valid
process
show
possibl
incorpor
requir
primer
singl
tube
assay
without
signific
loss
sensit
virus
result
shown
overal
pcr
assay
develop
abl
detect
least
tissu
cultur
infecti
dose
use
method
describ
result
shown
sensit
influenza
viru
influenza
b
viru
pcr
compon
respect
compar
combin
convent
assay
immunofluoresc
viru
isol
tabl
iii
howev
addit
test
use
matrix
specif
primer
shown
confirm
influenza
viru
pcr
positiveconvent
test
neg
sampl
true
posit
true
sensit
influenza
therefor
ci
specif
ci
influenza
b
sensit
ci
specif
ci
total
specimen
posit
picornavirus
pcr
neg
viru
isol
convent
test
avail
posit
result
picornavirus
confirm
use
enterovirusand
rhinovirusspecif
primer
give
assay
sensit
picornavirus
ci
specif
ci
although
base
small
number
instanc
sensit
pcr
assay
rsv
parainfluenza
virus
adenovirus
tabl
iii
specimen
collect
asymptomat
volunt
staff
neg
pcr
assay
figur
virus
pcr
avail
detect
time
overal
respiratori
virus
detect
specimen
receiv
test
viru
detect
rate
surveil
period
mayseptemb
offici
winter
month
juneaugust
shown
tabl
iv
greater
proport
virus
detect
surveil
patient
year
overlap
time
averag
winter
detect
rate
hospit
patient
decreas
summer
influenza
viru
common
viru
detect
fig
discret
winter
peak
occur
year
activ
viru
greater
identif
influenza
viru
rare
outsid
peak
incid
time
mayseptemb
picornavirus
second
common
viru
detect
influenza
viru
fig
detect
everi
month
year
although
common
cooler
month
although
screen
pcr
discrimin
rhinovirus
enterovirus
subgroup
picornavirusposit
specimen
collect
august
winter
collect
decemb
januaryfebruari
summer
rhinoviru
posit
retest
use
genusspecif
pcr
rsv
circul
discret
winter
peak
year
littl
activ
outsid
time
fig
circul
coronavirus
similar
rsv
although
peak
incid
year
approxim
one
month
later
coronavirus
compar
fig
c
commonli
detect
coronaviru
sporad
appear
mainli
autumn
spring
parainfluenza
virus
detect
low
number
throughout
year
tendenc
increas
detect
valid
hmpv
assay
sequenc
amplifi
product
describ
patient
method
b
includ
true
posit
see
result
sensit
influenza
ci
specif
ci
sensit
influenza
b
ci
specif
ci
sensit
picornavirus
ci
specif
ci
octob
novemb
adenovirus
detect
low
number
throughout
year
test
avail
hmpv
detect
highest
cooler
month
juneseptemb
proport
respiratori
virus
detect
accord
agegroup
whether
specimen
test
part
influenza
surveil
program
hospit
patient
shown
tabl
v
irrespect
sourc
specimen
individu
age
year
like
respiratori
viru
detect
adult
rate
detect
decreas
increas
age
pronounc
hospit
patient
common
virus
detect
hospit
patient
irrespect
age
influenza
picornavirus
hospit
children
year
age
hospit
adult
picornaviru
detect
rate
higher
influenza
surveil
patient
influenza
b
virus
togeth
account
least
virus
detect
age
group
sixti
three
patient
infect
virus
common
virus
implic
dual
infect
picornavirus
adenovirus
tabl
vi
picornavirus
present
anoth
viru
patient
repres
case
dual
infect
adenovirus
present
two
virus
detect
togeth
specimen
insuffici
clinic
inform
suppli
assess
influenc
dual
infect
degre
morbid
compar
patient
infect
singl
viru
studi
report
virolog
test
specimen
hospit
patient
communitybas
patient
part
victoria
annual
winter
influenza
surveil
program
overal
detect
rate
influenc
sourc
specimen
referr
higher
proport
specimen
surveil
hospit
patient
yield
recogn
respiratori
viru
introduct
nucleic
acid
detect
techniqu
diagnost
laboratori
decreas
time
diagnosi
mani
viral
infect
also
enabl
detect
one
pathogen
singl
specimen
use
individu
direct
pcr
multiplex
assay
billaud
et
al
echavarria
et
al
vuorinen
et
al
assay
also
increas
proport
specimen
aetiolog
agent
detect
evidenc
recent
discoveri
hmpv
van
den
hoogen
et
al
coronaviru
van
der
hoek
et
al
agent
replic
reliabl
cell
line
use
mani
diagnost
laboratori
expect
studi
influenza
virus
common
agent
identifi
although
virus
influenza
sometim
caus
influenzalik
ill
picornavirus
import
caus
morbid
hospit
surveil
patient
although
picornaviru
pcr
detect
enterovirus
rhinovirus
picornavirusposit
specimen
analys
includ
detect
summer
identifi
rhinovirus
although
pcrbase
assay
na
na
na
na
na
na
year
combin
detect
rate
virus
hospit
influenza
surveil
patient
shown
last
row
indic
low
asymptomat
carriag
rate
picornavirus
johnston
et
al
like
rhinovirus
detect
current
assay
caus
agent
ill
studi
need
analyz
sever
clinic
ill
associ
dual
infect
involv
rhinovirus
howev
abil
rhinovirus
produc
symptom
suffici
sever
mistaken
influenza
infect
sometim
requir
hospit
noteworthi
virus
associ
regularli
lower
respiratori
tract
infect
rsv
common
although
rsv
detect
commonli
hospit
children
expect
also
detect
regularli
adult
rsv
shown
previous
contribut
commun
hospit
case
influenzalik
ill
zambon
et
al
role
newli
identifi
hmpv
investig
viru
associ
mainli
hospit
case
suggest
may
clinic
distinguish
influenza
infect
commun
set
less
common
older
children
teenag
infant
young
children
adult
similar
epidemiolog
pattern
report
part
world
falsey
et
al
detail
studi
epidemiolog
viru
warrant
coronavirus
report
caus
case
common
cold
mcintosh
associ
hospit
among
older
adult
falsey
et
al
account
case
influenzalik
ill
particularli
younger
children
otherwis
present
surveil
patient
hospit
patient
role
caus
discret
outbreak
elderli
resid
agedcar
facil
describ
birch
et
al
press
studi
impact
newli
recogn
need
diagnost
test
algorithm
involv
multipl
target
anticip
sampl
would
contain
one
viru
virus
identifi
prolong
background
adenoviru
picornaviru
activ
throughout
year
period
surpris
therefor
virus
commonli
detect
part
dual
infect
rhinovirus
previous
shown
occur
commonli
rsv
case
acut
bronchiol
infanc
increas
risk
sever
diseas
papadopoulo
et
al
avail
pcr
technolog
provid
opportun
prospect
studi
epidemiolog
clinic
impact
dual
infect
respiratori
virus
lack
clinic
inform
suppli
time
specimen
receipt
unabl
link
mani
virolog
find
clinic
symptom
outcom
hospit
patient
howev
influenza
surveil
program
show
virus
especi
rhinovirus
often
associ
symptom
cough
fever
fatigu
found
rel
low
level
coronavirus
year
contrast
previou
report
studi
contribut
demonstr
import
pcr
investig
epidemiolog
laboratori
diagnosi
respiratori
viral
infect
pcr
assay
provid
opportun
identifi
new
virus
detect
replic
reliabl
cultur
cell
also
provid
rapid
sensit
mean
diagnosi
may
impact
treatment
durat
hospit
mani
case
hmpv
adenoviru
influenza
influenza
b
picornaviru
rsv
parainfluenza
hmpv
